Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS...

6
For more visit ResearchToPractice.com/5MJCBreast AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast Cancer Presentation discussed in this issue: Miles DW et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, Phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2009;Abstract 41. Editor’s comment: At the end of this slide set are several graphics with results from a recent Patterns of Care study of 100 US-based medical oncologists. Slides from a presentation at SABCS 2009

Transcript of Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS...

Page 1: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases

For more visit ResearchToPractice.com/5MJCBreast

AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast CancerPresentation discussed in this issue:

Miles DW et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, Phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2009;Abstract 41.

Editor’s comment: At the end of this slide set are several graphics with results from a recent Patterns of Care study of 100 US-based medical oncologists.

Slides from a presentation at SABCS 2009

http://researchtopractice.com/5MJC
http://researchtopractice.com/5MJCBreast#
http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_893
Page 2: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases

For more visit ResearchToPractice.com/5MJCBreast

http://researchtopractice.com/5MJC
http://researchtopractice.com/5MJCBreast#
Page 3: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases

For more visit ResearchToPractice.com/5MJCBreast

http://researchtopractice.com/5MJC
http://researchtopractice.com/5MJCBreast#
Page 4: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases

For more visit ResearchToPractice.com/5MJCBreast

http://researchtopractice.com/5MJC
http://researchtopractice.com/5MJCBreast#
Page 5: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases

For more visit ResearchToPractice.com/5MJCBreast

http://researchtopractice.com/5MJC
http://researchtopractice.com/5MJCBreast#
Page 6: Bevacizumab for HER2-Negative Metastatic Breast Cancer ......Source: Miles DW et al. SABCS 2009;Abstract 41. A 75-year-old with node+ trip neg BC presents with symptomatic metastases

For more visit ResearchToPractice.com/5MJCBreast

http://researchtopractice.com/5MJC
http://researchtopractice.com/5MJCBreast#

Inhibition of abnormal HER2-driven signaling by two HER2 ...€¦ · • These results suggest a new sub-group of breast cancer patients, HER2- with abnormal HER2 signaling (HER2-/HER2

Inhibition of abnormal HER2-driven signaling by two HER2 ...€¦ · • These results suggest a new sub-group of breast cancer patients, HER2- with abnormal HER2 signaling (HER2-/HER2

MFOLFOX-bevacizumab or XELOX- bevacizumab then bevacizumab alone or with erlotinib in 1st line treatment of patients with metastatic colorectal cancer.

MFOLFOX-bevacizumab or XELOX- bevacizumab then bevacizumab alone or with erlotinib in 1st line treatment of patients with metastatic colorectal cancer.

SABCS Congress webinar HR+/HER2- Advanced breast cancer ......• SABCS 2019 –Efficacy and safety –Extended and subgroup analyses ... •Abemaciclib plus fulvestrant led to a median

SABCS Congress webinar HR+/HER2- Advanced breast cancer ......• SABCS 2019 –Efficacy and safety –Extended and subgroup analyses ... •Abemaciclib plus fulvestrant led to a median

Bevacizumab in the treatment of ovarian cancer · 2017. 7. 14. · 4 bevacizumab for ovarian cancer kce report 285 8.1 unproven effectiveness of first-line bevacizumab on overall

Bevacizumab in the treatment of ovarian cancer · 2017. 7. 14. · 4 bevacizumab for ovarian cancer kce report 285 8.1 unproven effectiveness of first-line bevacizumab on overall

New Drug Development in HER2+ Breast Cancer › pdf › 3. AFTIMOS.pdf · The Trastuzumab (Herceptin®) Story 1979: HER2 oncogene discovery 1984: HER2 protein discovery 1987: HER2

New Drug Development in HER2+ Breast Cancer › pdf › 3. AFTIMOS.pdf · The Trastuzumab (Herceptin®) Story 1979: HER2 oncogene discovery 1984: HER2 protein discovery 1987: HER2

Activating HER2 Mutations in HER2 Gene ... - Cancer Discovery · 224 | CANCER DISCOVERYFEBRUARY 2013 Activating HER2 Mutations in HER2 Gene Amplifi cation Negative Breast Cancer

Activating HER2 Mutations in HER2 Gene ... - Cancer Discovery · 224 | CANCER DISCOVERYFEBRUARY 2013 Activating HER2 Mutations in HER2 Gene Amplifi cation Negative Breast Cancer

ComparativE˜ectivSafetMAntibodies (Bevacizumab,Cetuximab ...

ComparativE˜ectivSafetMAntibodies (Bevacizumab,Cetuximab ...

innovation for health Antibody to Bevacizumab (Avastin ...The Matriks Biotek Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-bevacizumab antibodies during therapy

innovation for health Antibody to Bevacizumab (Avastin ...The Matriks Biotek Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-bevacizumab antibodies during therapy

“An international scientific symposium ... - Home SABCS 2020 · SABCS iPosters is an online library that includes posters presented at the 2013 San Antonio Breast Cancer Symposium.

“An international scientific symposium ... - Home SABCS 2020 · SABCS iPosters is an online library that includes posters presented at the 2013 San Antonio Breast Cancer Symposium.

San Antonio Breast Cancer Symposium SABCS UPDATE - SABCS Update 2018_Brochure v2.pdf · Mothaffar Rimawi, M.D., Ph.D. ... Lectures F Panel Discussion F Question and Answer Sessions

San Antonio Breast Cancer Symposium SABCS UPDATE - SABCS Update 2018_Brochure v2.pdf · Mothaffar Rimawi, M.D., Ph.D. ... Lectures F Panel Discussion F Question and Answer Sessions

Therapeutic targeting of HER2 CB2R heteromers in HER2 ... · previously reported the presence of these complexes in HER2+ breast cancer tumors (12), but their role in HER2 function

Therapeutic targeting of HER2 CB2R heteromers in HER2 ... · previously reported the presence of these complexes in HER2+ breast cancer tumors (12), but their role in HER2 function

RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative.

RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative.

Baselga J et al. SABCS 2009;Abstract 45.

Baselga J et al. SABCS 2009;Abstract 45.

Vascular issues associated with bevacizumab

Vascular issues associated with bevacizumab

HER2-positive gastric cancer - Springer · 2017-08-27 · ‘‘HER2-positive gastric cancer,’’ similar to HER2-positive breast cancer. It is expected that more anti-HER2 drugs

HER2-positive gastric cancer - Springer · 2017-08-27 · ‘‘HER2-positive gastric cancer,’’ similar to HER2-positive breast cancer. It is expected that more anti-HER2 drugs

MCF10A Her2

MCF10A Her2

Aula Bevacizumab - Zulim

Aula Bevacizumab - Zulim

Role of the mTOR Pathway in Endocrine Therapy- Resistant Breast … · 2012. 3. 15. · Modified from W. Sellers at SABCS 2009. PTEN loss HER2 PI3K PTEN Growth Factors RAS PDK1 PTEN

Role of the mTOR Pathway in Endocrine Therapy- Resistant Breast … · 2012. 3. 15. · Modified from W. Sellers at SABCS 2009. PTEN loss HER2 PI3K PTEN Growth Factors RAS PDK1 PTEN

HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2 Gene ... · 2016-03-16 · HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2

HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2 Gene ... · 2016-03-16 · HER2 Gene Mutations in Non-Small Cell Lung Carcinomas: Concurrence with HER2

Maintenance Therapy for Advanced NSCLC · Bevacizumab pemetrexed cisplatin q3w Previously untreated stage IIIB/IV nonsquamous NSCLC Bevacizumab (7.5mg/kg) q3w Bevacizumab (7.5mg/kg)

Maintenance Therapy for Advanced NSCLC · Bevacizumab pemetrexed cisplatin q3w Previously untreated stage IIIB/IV nonsquamous NSCLC Bevacizumab (7.5mg/kg) q3w Bevacizumab (7.5mg/kg)